Keybanc Maintains Overweight on Certara, Raises Price Target to $12
10/16/2026
Impact: 70
Healthcare
Keybanc analyst Scott Schoenhaus has maintained an Overweight rating on Certara (NASDAQ: CERT) and raised the price target from $9 to $12. This adjustment reflects a positive outlook on the company's performance.
AI summary, not financial advice
Share: